Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: shinkai m. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.
Shinnakasu R, Sakakibara S, Yamamoto H, Wang PH, Moriyama S, Sax N, Ono C, Yamanaka A, Adachi Y, Onodera T, Sato T, Shinkai M, Suzuki R, Matsuura Y, Hashii N, Takahashi Y, Inoue T, Yamashita K, Kurosaki T. Shinnakasu R, et al. Among authors: shinkai m. J Exp Med. 2021 Dec 6;218(12):e20211003. doi: 10.1084/jem.20211003. Epub 2021 Oct 8. J Exp Med. 2021. PMID: 34623376 Free PMC article.
Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients.
Lu X, Hosono Y, Nagae M, Ishizuka S, Ishikawa E, Motooka D, Ozaki Y, Sax N, Maeda Y, Kato Y, Morita T, Shinnakasu R, Inoue T, Onodera T, Matsumura T, Shinkai M, Sato T, Nakamura S, Mori S, Kanda T, Nakayama EE, Shioda T, Kurosaki T, Takeda K, Kumanogoh A, Arase H, Nakagami H, Yamashita K, Takahashi Y, Yamasaki S. Lu X, et al. Among authors: shinkai m. J Exp Med. 2021 Dec 6;218(12):e20211327. doi: 10.1084/jem.20211327. Epub 2021 Oct 14. J Exp Med. 2021. PMID: 34647971 Free PMC article.
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine.
Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, Tonouchi K, Terahara K, Sun L, Takano T, Nishiyama A, Shinkai M, Oba K, Nakamura-Uchiyama F, Shimizu H, Suzuki T, Matsumura T, Isogawa M, Takahashi Y. Kotaki R, et al. Among authors: shinkai m. Sci Immunol. 2022 Apr 22;7(70):eabn8590. doi: 10.1126/sciimmunol.abn8590. Epub 2022 Apr 22. Sci Immunol. 2022. PMID: 35113654 Free PMC article.
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: shinkai m. iScience. 2023 Feb 17;26(2):105969. doi: 10.1016/j.isci.2023.105969. Epub 2023 Jan 13. iScience. 2023. PMID: 36687316 Free PMC article.
A case of reinfection with a different variant of SARS-CoV-2: case report.
Shimada N, Shinoda M, Takei H, Yoshida Y, Nishimura M, Kousaka M, Morikawa M, Sato T, Matsuse H, Shinkai M. Shimada N, et al. Among authors: shinkai m. Egypt J Intern Med. 2023;35(1):13. doi: 10.1186/s43162-023-00194-4. Epub 2023 Feb 8. Egypt J Intern Med. 2023. PMID: 36785595 Free PMC article.
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.
Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Takano T, et al. Among authors: shinkai m. Nat Commun. 2023 Mar 15;14(1):1451. doi: 10.1038/s41467-023-37128-1. Nat Commun. 2023. PMID: 36922492 Free PMC article.
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.
Onodera T, Sax N, Sato T, Adachi Y, Kotaki R, Inoue T, Shinnakasu R, Nakagawa T, Fukushi S, Terooatea T, Yoshikawa M, Tonouchi K, Nagakura T, Moriyama S, Matsumura T, Isogawa M, Terahara K, Takano T, Sun L, Nishiyama A, Omoto S, Shinkai M, Kurosaki T, Yamashita K, Takahashi Y. Onodera T, et al. Among authors: shinkai m. Sci Adv. 2023 Jun 16;9(24):eadf0661. doi: 10.1126/sciadv.adf0661. Epub 2023 Jun 14. Sci Adv. 2023. PMID: 37315144 Free PMC article.
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M. Sonoyama T, et al. Among authors: shinkai m. Vaccine. 2023 Mar 10;41(11):1834-1847. doi: 10.1016/j.vaccine.2022.12.025. Epub 2022 Dec 16. Vaccine. 2023. PMID: 36572603 Free PMC article. Clinical Trial.
High Fever, Wide Distribution of Viral Pneumonia, and Pleural Effusion are More Critical Findings at the First Visit in Predicting the Prognosis of COVID-19: A Single Center, retrospective, Propensity Score-Matched Case-Control Study.
Shinoda M, Ota S, Yoshida Y, Hirouchi T, Shinada K, Sato T, Morikawa M, Ishii N, Shinkai M. Shinoda M, et al. Among authors: shinkai m. Int J Gen Med. 2023 Jun 8;16:2337-2348. doi: 10.2147/IJGM.S408907. eCollection 2023. Int J Gen Med. 2023. PMID: 37313043 Free PMC article.
317 results